Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Innoviva closes $250mm Term B loan

Executive Summary

Just two weeks after raising $192.5mm through a convertible debt sale, Innoviva Inc. (respiratory therapies) closed a $250mm Term B loan that matures in August 2022, bears interest at a rate equal to LIBOR plus 4.5%, and requires a 10% minimum annual principal repayment. The company will use the proceeds to refinance its 9.0% fixed rate term notes due 2029.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt
    • Private Placement

Related Companies